The Postgraduate Institute for Medicine designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Postgraduate Institute of Medicine designates this continuing education activity for 1.0 contact hour (0.1 CEUs) of the Accreditation Council for Pharmacy Education. University Activity Number: JA4008162-9999-20-1069-L01-PType of Activity: Knowledge
The maximum number of hours awarded for this Continuing Nursing Education activity is 1.0 contact hour. Designated for 1.0 contact hour of pharmacotherapy credit for Advanced Practice Registered Nurses.
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 MOC point in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
Hardware/Software RequirementsThe webinar is accessed through GoToWebinar. An internet connection and the system requirements are needed to access the webinar.Policy on Privacy and ConfidentialityPlease see final activity for the policy on privacy and confidentiality that relates to this internet activity.Disclosure of Conflicts of Interest
Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. PIM is committed to providing its learners with high quality activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.
Upon completion of this program, participants will be able to:
Describe advances in immune checkpoint inhibitor therapies for highly immunotherapy-responsive cancers including melanoma, non-small cell lung cancer, and renal cell carcinoma
Outline the application of immune checkpoint inhibitor therapies for less-explored indications, such as in triple-negative breast cancer and hepatocellular carcinoma
Explain the rationale behind and implications of current combination immunotherapy studies
Either the content you're seeking doesn't exist or it requires proper authentication before viewing.
Tel: +1 414 271 2456 | Fax: +1 414 276 3349 | Email: email@example.com